These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 20495466)

  • 1. Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine.
    Kao J; Kwok K; Das KM
    J Clin Gastroenterol; 2010 Sep; 44(8):531-5. PubMed ID: 20495466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
    Cohen HD; Das KM
    J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S150-4. PubMed ID: 16885699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
    Sandborn WJ
    Rev Gastroenterol Disord; 2006; 6(2):97-105. PubMed ID: 16699478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
    Med Lett Drugs Ther; 2009 May; 51(1312):38-9. PubMed ID: 19448588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
    Hanauer SB
    Aliment Pharmacol Ther; 2006 Oct; 24 Suppl 3():37-40. PubMed ID: 16961743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
    Marshall JK; Irvine EJ
    Am J Gastroenterol; 2000 Jul; 95(7):1628-36. PubMed ID: 10925961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reformulation of an aminosalicylate: an example of the importance of pill burden on medical compliance rates.
    Osterman MT; Lichtenstein GR
    Methods Find Exp Clin Pharmacol; 2009; 31(1):41-6. PubMed ID: 19357797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug therapy for ulcerative colitis: salazosulfapyridine and 5-ASA].
    Jo Y; Matsumoto T; Iida M
    Nihon Rinsho; 2005 May; 63(5):820-4. PubMed ID: 15881176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
    Safdi AV; Cohen RD
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1179-86. PubMed ID: 17944732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
    Kam L; Cohen H; Dooley C; Rubin P; Orchard J
    Am J Gastroenterol; 1996 Jul; 91(7):1338-42. PubMed ID: 8677990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
    Schroeder KW
    Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesalamine with MMX technology for the treatment of ulcerative colitis.
    Schreiber S; Kamm MA; Lichtenstein GR
    Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials.
    Zhu Y; Tang RK; Zhao P; Zhu SS; Li YG; Li JB
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):487-94. PubMed ID: 22465970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MMX mesalamine.
    Baker DE
    Rev Gastroenterol Disord; 2006; 6(3):146-52. PubMed ID: 16957657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
    Cohen RD; Woseth DM; Thisted RA; Hanauer SB
    Am J Gastroenterol; 2000 May; 95(5):1263-76. PubMed ID: 10811338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
    Habal FM; Greenberg GR
    Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.